Therachon
WebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome … Webb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit …
Therachon
Did you know?
WebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and … Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024
WebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … Webb26 mars 2024 · We gave two presentations on investigational apraglutide for the treatment of #ShortBowelSyndrome at #ASPEN19!1. Complete Ph 1 trial results 2. Data from head-to-head rat studies comparing apraglutide to other GLP-2 analogs.
Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development … WebbTherachon is a global biotechnology company (headquartered in Basel) committed to making a difference in the lives of patients living with serious rare conditions. Therachon …
Webb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ...
WebbTherachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. We are committed to the … gps will be named and shamedWebb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … gps west marineWebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 gps winceWebb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holdin gps weather mapWebb9 okt. 2024 · BASEL, Switzerland, Oct. 9, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the ... gpswillyWebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions … gps w farming simulator 22 link w opisieWebbTherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant protein therapy for achondroplasia, the most … gps wilhelmshaven duales studium